In this retrospective study, I was given a population of Pro Cancer patients to examine where the PSA levels and Testosterone levels occurred after treatment with Lutienizing Hormone Releasing Hormone Agonist. The population set was approximately 489 and the subsets included patients who reached castration level and those who did not during treatment protocols. Two groups were identified: treatment failure and success at castration based on PSA levels. Follow up on non-castration level patients will be done to evaluate PSA levels and also evaluate two groups based on success of treatment and failure to abate the prostate cancer. Analysis will be performed and power study implemented following the success of the study based on file from 1990 to 2010..